Clinical Trials Browser

Completed × Epirubicin × 1 year × Clear all

NCT04433156 2026-04-09

VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma

Phase 2 Completed

Lymphoma, B-Cell, Marginal Zone

NCT04877821 2026-04-02

NeoSACT

Phase 2 Completed

Triple Negative Breast Neoplasms

NCT00066443 2026-03-27

Epirubicin, Docetaxel, and Pegfilgrastim in Treating Women With Locally Advanced or Inflammatory Breast Cancer

Phase 1/2 Completed

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT01358877 2025-11-28

APHINITY

Phase 3 Completed

4,804 enrolled 45 charts 2 FDA

Breast Neoplasms

NCT04214626 2025-11-19

R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma

Phase 2 Completed

Lymphoma, Large B-Cell, Diffuse

NCT03036488 2025-10-29

MK-3475-522

Phase 3 Completed

1,174 enrolled 2 FDA

Triple Negative Breast Neoplasms

NCT00872625 2025-09-30

Radiation Therapy and Docetaxel Followed by Standard Therapy in Treating Women With Breast Cancer

Phase 1 Completed

Breast Neoplasms

NCT01630083 2025-06-15

FAST

Phase 2 Completed

Gastrointestinal

CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction